

Unlocking the Code: When SpliceAI Falls Short in Variant Assessment



Jessica Grzybowski, MS, CGC; Meghan C. Towne, MS, CGC; Brooklynn Gasser, MS; Melissa Samons, MS, CGC; Carolyn Horton, MS, CGC; Jesus Ramirez Castano, BS; Kevin Lam, BS, ASCP(MB), CGMBS; Bhuvan Molparia, PhD; hzimmermann@ambrygen.com

Ambry Genetics, Aliso Viejo, CA

BACKGROUND


- RNA splicing involves intricate biological mechanisms and predicting how a variant will impact this process is particularly challenging.
- Splice prediction algorithms, like SpliceAI, are helpful but not definitive for predicting splicing impacts.
- Incorporating RNA data is essential for accurate variant interpretation.

Aims: Describe 5 cases with clinically relevant variants with observed splicing impacts that were not predicted by SpliceAI based on the commonly accepted benign threshold of 0.1.^{1,2}

TAKE HOME POINTS

- Variants with low SpliceAI scores can still result in clinically relevant splicing alterations.
- Reliance solely on *in silico* predictions can lead to variant misclassification.
- RNA analysis provides detailed insights into splicing alterations and improves interpretation accuracy.

METHODS & RESULTS



- 5 variants with splice predictions below the typical benign threshold were identified in cases with clinical features consistent with variant pathogenicity [Figure 1]
- RNA studies detected substantial aberrant splicing in all 5 cases [representative cases in Figure 2]
- Incorporation of RNA evidence leads to clinically significant upgrades (VUS to P/LP) [Table 1]

FIGURE 1: SPLICEAI THRESHOLDS^{1,2}




TABLE 1: IMPACT OF RNA EVIDENCE

Case ID	Variant (Location)	SpliceAI ² DL = donor loss AL = acceptor loss	PSI (Percent spliced in) (ESF = full exon skip)	- RNA	+ RNA
1	<i>JAG1</i> c.886+3A>G (Intronic)	DL = 0	43.22% ESF4 5.29% ESF4-5	VUS	LP ³
2	<i>NF1</i> c.6084G>A p.K2028K (Last nucleotide)	DL = 0.08	37.42% ESF40 8.45% ESF40-41 0% A allele	VUS	P
3	<i>CDH1</i> c.1613A>T p.D538V (Mid-exonic)	AL = 0.01	45.56% ESF13 3% T allele	VUS	LP
4	<i>APC</i> c.1744-22C>G (Intronic)	AL = 0.07	64.62% ESF	VUS	P
5	<i>PMS2</i> c.1144G>C p.G382R (Last nucleotide)	DL = 0.02	45.64% ESF 2% C allele	VUS ⁴	P

FIGURE 2: RNA STUDIES RESULTS

